GRACE :: Lung Cancer
GRACE Video

Acquired Resistance Patient Forum 2014 Videos

Share
 
In September 2014, GRACE gathered experts in Acquired Resistance for ALK/ROS1/EGFR positive lung cancer to lead a patient forum. Speakers were Bonnie Addario, Dr. Gideon Blumenthal, ‘Craig in PA’, Dr. Robert Doebele, Dr. Pasi Jänne, Dr. Melissa Johnson, Dr. Nate Pennell, Dr. Greg Riely, Dr. Lecia Sequist, Dr. Alice Shaw, Dr. Jack West, and Dr. Jared Weiss.
 
Acquired Resistance Patient Forum Guest Speakers
 
Please note, the information presented below was accurate in September 2014, but progress in Acquired Resistance for ALK/ROS1/EGFR positive treatments moves quickly. If you have questions about the information in these videos, please post them in the GRACE forum.
 

What is Acquired Resistance and How Does it Occur?
What is Acquired Resistance and How Does it Occur?
20:13
Acquired Resistance Forum Video #1: Dr. Gregory J. Riely of Memoral Sloan Kettering Cancer Center opened the Acquired Resistance in Lung Cancer Patient Forum with a basic introduction of how ALK, ROS1 and EGFR lung cancers become resistant to treatment. September 2014
 
Life After 1st Line Targeted Therapy: What Next?
Life After 1st Line Targeted Therapy: What Next?
25:09
 
Acquired Resistance Forum Video #2: Dr. Jared Weiss of the University of North Carolina addressed the Acquired Resistance in Lung Cancer Patient Forum with information on what patients’ options are when their ALK, ROS1 or EGFR lung cancer progresses. September 2014
 
Repeat Biopsies & the Potential Value of Biologically-Informed Acquired Resistance Therapy
Repeat Biopsies & the Potential Value of Biologically-Informed Acquired Resistance Therapy
24:29
 
Acquired Resistance Forum Video #3: Dr. Lecia Sequist of Massachusetts General Hospital detailed why doctors started doing repeat biopsies for patients receiving targeted therapies and how they help patients and doctors determine next steps in treatment.
 
Questions & Answers with Drs. Riely, Weiss and Sequist; Moderated by Dr. West
Questions & Answers with Drs. Riely, Weiss and Sequist; Moderated by Dr. West
29:05
 
Acquired Resistance Forum Video #4: The first three speakers at the Acquired Resistance in Lung Cancer Patient Forum sat for a moderated Q&A with Dr. Jack West.
 
Clinical Trial Design & Development of Highly Targeted Agents in the Molecular Era
Clinical Trial Design & Development of Highly Targeted Agents in the Molecular Era
24:37
 
Acquired Resistance Forum Video #5: Dr. Gideon Blumenthal of the US Food and Drug Administration (FDA) discussed the FDA process for approving targeted therapies.
 
Using Non/Off-Targeted Therapies in Targeted Lung Cancer Populations
Using Non/Off-Targeted Therapies in Targeted Lung Cancer Populations
25:13
 
Acquired Resistance Forum Video #6: Dr. Nate Pennell of the Cleveland Clinic discussed the other options available to patients with ALK, ROS1 and EGFR lung cancer, such as chemotherapy, Avastin, and immunotherapy.
 
Questions & Answers with Drs. Blumenthal and Pennell; Moderated by Dr. West
Questions & Answers with Drs. Blumenthal and Pennell; Moderated by Dr. West
16:41
 
Acquired Resistance Forum Video #7: Speakers from videos #5 and #6 at the Acquired Resistance in Lung Cancer Patient Forum sat for a moderated Q&A with Dr. Jack West.
 
Mechanisms of ALK Resistance & Implications for Treatment
Mechanisms of ALK Resistance & Implications for Treatment
22:46
 
Acquired Resistance Forum Video #8: Dr. Robert Doebele of the University of Colorado Cancer Center spoke to ALK and ROS1 patients about how and why their cancers become resistant to treatment and what options are available.
 
Current and Emerging Approaches to Acquired Resistance for ALK/ROS1
Current and Emerging Approaches to Acquired Resistance for ALK/ROS1
29:50
 
Acquired Resistance Forum Video #9: Dr. Alice Shaw of Massachusetts General Hospital detailed for patients the so-called “next generation” ALK/ROS1 inhibitors, both those commercially available and those still in development.
 
Questions & Answers with Drs. Doebele and Shaw; Moderated by Craig Uthe
Questions & Answers with Drs. Doebele and Shaw; Moderated by Craig Uthe
13:49
 
Acquired Resistance Forum Video #10: Online advocate and ROS1 patient “Craig In PA” Uthe leads a Q&A with speakers from videos #8 and #9 at the Acquired Resistance in Lung Cancer Patient Forum.
 
Leveraging Patient Engagement & the Role of Advocacy
Leveraging Patient Engagement & the Role of Advocacy
19:56
 
Acquired Resistance Forum Video #11: Bonnie J. Addario, founder of the Addario Lung Cancer Foundation described how the lung cancer community can work together to support each other and affect change for all patients.
 
The Expanding Role of Patient Self-Education & Online Communities in Molecularly Defined Subgroups
The Expanding Role of Patient Self-Education & Online Communities in Molecularly Defined Subgroups
24:30
 
Acquired Resistance Forum Video #12: Online advocate and ROS1 patient “Craig In PA” Uthe detailed how patients can educate themselves about their disease to understand and improve their personal situations. He also included his favorite online resources.
 
Cost of & Access to Molecularly Targeted Therapies as Barriers to Optimal Care
Cost of & Access to Molecularly Targeted Therapies as Barriers to Optimal Care
12:20
 
Acquired Resistance Forum Video #13: Dr. Jack West of Swedish Cancer Institute discussed how the skyrocketing costs of cancer care are impacting whether or not some patients are able to get the right treatments.
 
Questions & Answers with Bonnie Addario and Craig Uthe; Moderated by Dr. Jack West
Questions & Answers with Bonnie Addario and Craig Uthe; Moderated by Dr. Jack West
24:21
 
Acquired Resistance Forum Video #14: Speakers from video #11 and video #12 at the Acquired Resistance in Lung Cancer Patient Forum sat for a moderated Q&A with Dr. Jack West.
 
Novel EGFR Inhibitors in the Setting of Acquired Resistance
Novel EGFR Inhibitors in the Setting of Acquired Resistance
26:26
 
Acquired Resistance Forum Video #15: Dr. Pasi Jänne of Dana-Farber Cancer Institute spoke about EGFR inhibitors available to patients when Tarceva stops working for them.
 
 
 

Ask Us, Q&A
Lung/Thoracic Cancer Expert Content

Archives

Share

GRACE Cancer Video Library - Lung Cancer Videos

 

2015_Immunotherapy_Forum_Videos

 

2015 Acquired Resistance in Lung Cancer Patient Forum Videos

Share

Join the GRACE Faculty

Breast Cancer Blog
Pancreatic Cancer Blog
Kidney Cancer Blog
Bladder Cancer Blog
Head/Neck Cancer Blog
Share

Subscribe to the GRACEcast Podcast on iTunes

Share

Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon

Subscribe to
GRACE Notes
   (Free Newsletter)

Other Resources

Share

ClinicalTrials.gov


Biomedical Learning Institute

peerview_institute_logo_243